A phase 1b trial in non-metastatic pancreatic cancer patients suggests that CCR2 inhibition decreases tumor-infiltrating macrophages and regulatory T cells, while also increasing effector T cells58. This evidence concerns the gene CCR2 and pancreatic neoplasm.